The discoveries still ahead of us.
Every discovery becomes the starting point for the next. Horizons is where we look toward the future Arc is helping to create.
Discovery compounds.
Each connection reveals the next.
We do not measure our future in a single product, or a single year. We measure it in the widening network of what becomes possible, each advance linking to another.
These are the horizons we are moving toward: not destinations, but directions of travel along the arc of human discovery.
Where it all connects
Each advance links to another, the way the points of a constellation resolve into a shape only once you step back.
What lies ahead
Medicine that meets people where they are. Care that reaches further than it ever has. A science of wellbeing that lasts a whole life long, and discoveries we cannot yet name.
Where the arc leads
The fields we are moving toward.
Beyond the pill
New ways for medicine to reach the body, gentler, faster, and designed around the realities of human life rather than the limits of old formats.
Care without barriers
Closing the distance between scientific possibility and the people who need it, wherever they are, whatever their circumstance.
Health, not just treatment
Extending discovery into the everyday, supporting the wellbeing people keep across a lifetime, not only the illness they treat.
Sciences yet to come
The most important discoveries are the ones we cannot yet name, and the arc obliges us to keep moving toward them.
The pipeline
The programs in development.
The programs Arc is advancing across its areas of focus, each defined by the patients it could serve and the science behind it. Filter by area, and press a program to see how it works.
Allergic Rhinitis and Chronic Urticaria.
Selective peripheral histamine H1 receptor antagonism.
Selectively blocks peripheral H1 receptors to interrupt the histamine cascade that drives allergic symptoms, with minimal central effect.
Millions live with daily allergic symptoms. A more selective approach aims to deliver relief without the drowsiness that limits everyday function.
Allergic respiratory disease and inflammatory airway conditions.
Cysteinyl leukotriene receptor antagonism.
Blocks the leukotriene receptors that mediate airway inflammation and constriction in allergic respiratory disease.
Inflammatory airway conditions affect breathing and rest. Targeting the inflammatory pathway directly offers a route to more consistent control.
Immune-mediated inflammatory disorders.
TNF-α inhibition.
Neutralizes a central inflammatory signalling protein implicated in a range of immune-mediated inflammatory disorders.
Chronic inflammatory disease can be life-altering. Modulating a key driver of inflammation aims to change the course of disease, not just its symptoms.
Acute migraine intervention.
Serotonin 5-HT1B/1D receptor agonism.
Activates 5-HT1B/1D receptors to constrict dilated cranial vessels and dampen the neural signalling that drives acute migraine.
Migraine is among the leading causes of disability worldwide. Rapid, dependable intervention can return lost hours to the people it affects.
Thromboembolic risk reduction and cardiovascular protection.
Selective Factor Xa inhibition.
Selectively inhibits a key clotting factor to reduce thrombotic risk while aiming to preserve a favourable safety profile.
Thromboembolic events are a leading cause of mortality. Reliable, well-tolerated protection can prevent life-changing events before they occur.
Appetite regulation, metabolic health, weight management and glycemic control.
Dual incretin receptor agonism.
Engages two complementary incretin pathways to regulate appetite, glucose and energy balance.
Obesity and metabolic disease affect hundreds of millions. Addressing multiple pathways at once offers a more complete approach to metabolic health.
Targeted nutritional support.
Targeted nutritional intervention and advanced nutritional delivery approaches.
Combines targeted micronutrient science with advanced delivery to improve absorption, convenience and adherence.
Nutritional gaps quietly affect daily vitality. Making correction effortless helps people sustain wellbeing across a lifetime.
Seasonal influenza prevention.
Immune stimulation through next-generation vaccine delivery technologies.
Stimulates protective immunity using a delivery technology designed to simplify administration and broaden access.
Seasonal influenza causes significant illness each year. Easier delivery can extend protection to more people, more reliably.
Respiratory viral disease prevention.
Advanced antigen delivery approaches.
Presents viral antigens through an advanced delivery approach intended to elicit a durable protective response.
Respiratory viruses place a heavy burden on health systems. Better prevention reduces illness and protects the vulnerable.
Typhoid prevention.
Targeted immunization technologies.
Uses targeted immunization technology to generate protection against typhoid infection.
Typhoid remains a serious threat in many regions. Accessible immunization can prevent widespread, preventable illness.
Measles and Rubella prevention.
Long-term protective immunization strategies.
Builds durable, long-term protective immunity against measles and rubella.
Sustained immunization is essential to keep these diseases in retreat and protect future generations.
Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia.
Phosphodiesterase Type-5 inhibition.
Inhibits PDE-5 to enhance smooth-muscle relaxation and blood flow, addressing both ED and BPH-related urinary symptoms.
These conditions affect confidence and quality of life. A discreet, dual-benefit approach meets a need many are reluctant to voice.
Digestive wellbeing and patient experience.
Novel gastrointestinal support approaches focused on digestive wellbeing and patient experience.
Supports digestive comfort through a novel approach designed around real patient experience rather than a single symptom.
Digestive discomfort shapes daily life for millions. Centering the patient experience opens a more humane path to relief.
Acute inflammatory pain management and rapid symptom control.
Cyclooxygenase inhibition.
Inhibits the cyclooxygenase enzymes that generate inflammatory pain signals, for rapid control of acute pain.
Acute pain disrupts recovery and daily life. Fast, dependable relief helps people return to themselves sooner.
The breakthrough is only half the work. The rest is making it livable.
The most important platform is the one we have not built yet.
What comes next